{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"index.html","title":"Welcome to GrowthXInfinity","text":"<p>Deep, practical docs on portfolios, growth, and infinite learning for everyone.</p> <p></p> <ul> <li>Blogs</li> </ul>"},{"location":"blogs/index.html","title":"Blogs","text":"<p>Deep, practical docs on portfolios, growth, and infinite learning for everyone.</p> <p></p> <ul> <li>22-02-2026 Chandan Healthcare = Vaibhav Suryaavanshi of Indian Diagnostics? \ud83c\udfcf</li> </ul>"},{"location":"blogs/22022026chandanhealthcare.html","title":"Chandan Healthcare = Vaibhav Suryaavanshi of Indian Diagnostics? \ud83c\udfcf","text":"<p>Some companies defend. Some attack.  </p> <p>Chandan Healthcare is clearly playing in the powerplay.</p> <p>Author: Priyanshu Jain ,Date: 2026-02-22</p>"},{"location":"blogs/22022026chandanhealthcare.html#q3-fy26-snapshot","title":"\ud83d\udcca Q3 FY26 Snapshot","text":"Metric Value Growth Revenue \u20b965.77 Cr +20% YoY EBITDA \u20b912.61 Cr +39% YoY EBITDA Margin 19.17% \u2014 PAT \u20b94.54 Cr \u2014 <p>Note: \u20b92.2 Cr one-time gratuity impact due to new labour code.</p>"},{"location":"blogs/22022026chandanhealthcare.html#business-model-not-asset-light-not-minimal","title":"\ud83c\udfe5 Business Model: Not Asset-Light. Not Minimal.","text":"<p>Unlike traditional asset-light diagnostic chains, Chandan builds 8,000\u20139,000 sq ft comprehensive centres offering:</p> <ul> <li>Pathology  </li> <li>Radiology (MRI, CT)  </li> <li>Corporate health check-ups  </li> <li>Government PPP projects  </li> <li>Direct B2C services  </li> <li>Franchise network  </li> </ul> <p>Everything under one roof.</p>"},{"location":"blogs/22022026chandanhealthcare.html#segment-ebitda-potential","title":"\ud83d\udcb0 Segment EBITDA Potential","text":"Segment EBITDA Potential B2C (Mature Centres) 40\u201345% B2G 30\u201340% B2B / Franchise ~35% <p>As centres mature \u2192 Operating leverage improves significantly.</p> <p>Same infra. Higher utilisation. Better margins.</p>"},{"location":"blogs/22022026chandanhealthcare.html#expansion-mode-on","title":"\ud83d\ude80 Expansion Mode: ON","text":"<ul> <li>6 comprehensive centres added  </li> <li>18 labs launched  </li> <li>Presence in 13 states  </li> <li>9 new labs launching  </li> <li>Genome Lab (Lucknow)  </li> <li>PET Scan facility (Gorakhpur)</li> </ul>"},{"location":"blogs/22022026chandanhealthcare.html#capex-plan","title":"Capex Plan","text":"<p>\u20b9100 Cr over 3 years ~\u20b91 Cr per lab</p>"},{"location":"blogs/22022026chandanhealthcare.html#jeena-sikho-partnership","title":"\ud83e\udd1d Jeena Sikho Partnership","text":"<ul> <li>\u20b92.5\u20133 lakh/day revenue currently  </li> <li>~30% utilisation  </li> <li>Target: 100% utilisation within 1 year  </li> </ul> <p>If utilisation scales \u2192 margin expansion follows.</p>"},{"location":"blogs/22022026chandanhealthcare.html#big-trigger-punjab-guwahati-project","title":"\ud83d\udd25 Big Trigger: Punjab + Guwahati Project","text":"<ul> <li>\u20b955 Cr annual revenue visibility  </li> <li>10-year contract  </li> <li>Cash collected directly from patients  </li> </ul> <p>If executed well \u2014 FY27 could look very different.</p>"},{"location":"blogs/22022026chandanhealthcare.html#strategic-positioning","title":"\ud83c\udfaf Strategic Positioning","text":"<p>They\u2019re not copying Dr Lal PathLabs. They\u2019re building their own integrated format.</p> <p>Young. Aggressive. Scaling fast.</p> <p>Like Vaibhav Suryaavanshi \u2014 Not waiting for the pitch to settle.</p>"},{"location":"blogs/22022026chandanhealthcare.html#final-thoughts","title":"\ud83e\udde0 Final Thoughts","text":"<p>Execution will decide whether ambition converts into sustained profitability.</p> <p>But one thing is clear:</p> <p>Chandan Healthcare is not playing defensively.</p> <p>It\u2019s playing to dominate early overs.</p> <pre><code>flowchart TD\n    A[Chandan Healthcare&lt;br&gt;Integrated Diagnostic Model] \n\n    A --&gt; B[High Capex Comprehensive Centres&lt;br&gt;8000 to 9000 sq ft]\n\n    B --&gt; C1[B2C Services&lt;br&gt;40\u201345% EBITDA Potential]\n    B --&gt; C2[B2G PPP Contracts&lt;br&gt;30\u201340% EBITDA Potential]\n    B --&gt; C3[B2B Franchise&lt;br&gt;~35% EBITDA Potential]\n\n    C1 --&gt; D[Volume Growth]\n    C2 --&gt; D\n    C3 --&gt; D\n\n    D --&gt; E[Higher Utilisation]\n    E --&gt; F[Operating Leverage]\n    F --&gt; G[Margin Expansion]\n\n    G --&gt; H[Stronger Cash Flows]\n    H --&gt; I[Expansion: New Labs + Genome + PET + Punjab/Guwahati]\n\n    I --&gt; A</code></pre>"},{"location":"blogs/22022026chandanhealthcare.html#whats-your-view-on-emerging-diagnostic-players-beyond-the-obvious-giants","title":"What\u2019s your view on emerging diagnostic players beyond the obvious giants?","text":""}]}